SLX-3064

SLX-3064: sourced facts only. name: "The SLX-3064 and SLX-3065 reversibly bind to CDK9 with an IC50 of 9 and 7 nM in kinase binding, in target engagement assays, elicit pharmacological responses in N-MYC, C-MYC, driven prostate cancer cells in vitro in LASCPC-01 (21, 35 nM), 22Rv1 (108, 236 nM), C4-2B (15, 12 nM), C4-2 (2.7, 1.5 nM) and VCap (86, 73 nM) cell lines." [DOI:10.1158/1538-7445.am2024-lb161]; target: "The SLX-3064 and SLX-3065 reversibly bind to CDK9 with an IC50 of 9 and 7 nM in kinase binding, in target engagement assays, elicit pharmacological responses in N-MYC, C-MYC, driven prostate cancer cells in vitro in LASCPC-01 (21, 35 nM), 22Rv1 (108, 236 nM), C4-2B (15, 12 nM), C4-2 (2.7, 1.5 nM) and VCap (86, 73 nM) cell lines." [DOI:10.1158/1538-7445.am2024-lb161]; developer: "1Biolexis Therapeutics Inc., American Fork, UT." [DOI:10.1158/1538-7445.am2024-lb161]; modality: "We designed and synthesized a series of novel small molecule CDK9 Molecular Glue degraders based on our initial CDK9 inhibitor lead SLX-3030 and SLX-3039." [DOI:10.1158/1538-7445.am2024-lb161]